BioNTech

BioNTech SE (Biopharmaceutical New Technologies), headquartered in Mainz, Germany, is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Founded in 2008 by renowned physician-scientists, including Uğur Şahin and Özlem Türeci, BioNTech is driven by the vision of individualizing cancer medicine. The company boasts an incredibly diverse technological arsenal that goes far beyond its famous messenger RNA (mRNA) platform; its research encompasses targeted antibodies, advanced cell therapies (CAR-T), and small molecule immunomodulators.

BioNTech gained immense global prominence by developing the first FDA-approved COVID-19 vaccine (Comirnaty) in a historic partnership with Pfizer, proving the safety and monumental efficacy of mRNA technology on a global scale. However, the company’s deepest roots and future ambitions remain firmly planted in oncology.

BioNTech is at the absolute forefront of developing individualized mRNA cancer vaccines (such as its iNeST platform) that train the immune system to recognize and destroy specific tumor mutations. Additionally, they are advancing FixVac platforms targeting shared tumor antigens in cancers like melanoma and prostate cancer.

BioNTech operates state-of-the-art manufacturing facilities across Germany (including Marburg and Idar-Oberstein) and is expanding into the US, UK, and Asia to support global clinical trials and commercialization. By seamlessly integrating profound immunological insights, cutting-edge computational biology, and rapid manufacturing technologies, BioNTech is leading a paradigm shift towards highly personalized, highly effective immunotherapies.